Mycobacterium Tuberculosis Market Report 2026

The mycobacterium tuberculosis market size has grown strongly in recent years. It will grow from $3.73 billion in 2025 to $3.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to high tb incidence in developing regions, widespread adoption of culture-based testing, increased investment in public health programs, rise in global disease surveillance, early development of pcr-based methods.

The mycobacterium tuberculosis market size is expected to see steady growth in the next few years. It will grow to $4.75 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growth in molecular diagnostics usage, expansion of telemedicine-based tb screening, rising demand for rapid detection kits, increasing government funding for tb elimination, advancement in automated detection systems. Major trends in the forecast period include growing adoption of molecular tb diagnostic technologies, increasing use of rapid antigen and antibody test kits, expansion of culture-based testing in high-burden regions, rising demand for tb screening in research and public health programs, higher utilization of reagents and consumables for routine tb testing.

The increasing level of investment in research and development is expected to propel the growth of the mycobacterium tuberculosis market going forward. Research and development involves generating new knowledge or enhancing existing products, services, and technologies through systematic study and experimentation. The expansion of research and development activities is largely driven by rapid technological progress, which creates a continuous need for innovation to remain competitive in global markets. In the context of mycobacterium tuberculosis, research and development efforts support treatment advancement by enabling the discovery of new drug candidates capable of overcoming resistance to existing therapies, thereby improving treatment efficacy and patient outcomes. For instance, in March 2024, according to a report published by the Foreign, Commonwealth, and Development Office, a UK-based government department, the UK government announced a $5 million (£4 million) funding increase for the TB REACH program to support innovative approaches for improving tuberculosis diagnosis and treatment in low- and middle-income countries. Through this initiative, 500,000 people are expected to receive healthcare services, 37,000 individuals will have tuberculosis detected, and more than 15,000 lives may potentially be saved. Therefore, rising investments in research and development are driving the growth of the mycobacterium tuberculosis market.

Major companies operating in the mycobacterium tuberculosis market are concentrating on the development of advanced solutions, such as automated tuberculosis testing systems, to deliver faster and more accurate diagnostic results. Automated tuberculosis tests are diagnostic tools that utilize automated processes and advanced technologies to quickly and precisely identify Mycobacterium tuberculosis and drug resistance with minimal manual involvement. For instance, in April 2025, Revvity Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved the Auto-Pure 2400 liquid handling platform for use with the T-SPOT.TB test. The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test enhances automated tuberculosis testing by enabling higher sample throughput without compromising accuracy. The system combines liquid handling with magnetic cell isolation technology, allowing up to 24 samples per run and completing the first day of testing in under 3.5 hours with minimal user intervention. The T-SPOT.TB test, recognized by the World Health Organization as the only ELISPOT-based IGRA, delivers reproducible results with fewer indeterminate outcomes, reduces the need for repeat testing, and performs reliably in immunocompromised patients.

In November 2023, Becton, Dickinson and Company (BD), a US-based provider of tuberculosis diagnostic solutions, collaborated with Bio Farma to support Indonesia’s efforts to eliminate the spread of tuberculosis. This collaboration aims to improve access to BD’s innovative tuberculosis diagnostics portfolio while strengthening the supply chain for TB solutions within Indonesia. The partnership also enables Bio Farma to expand its expertise in the development of diagnostic kits. Bio Farma is an Indonesia-based manufacturer of tuberculosis vaccines.

Major companies operating in the mycobacterium tuberculosis market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Macleods Pharmaceuticals Limited, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Lupin Limited, Zydus Cadila Healthcare Limited, Cepheid Inc., Serum Institute of India Pvt. Ltd., Oxford Immunotec USA Inc., Panacea Biotec Limited, International AIDS Vaccine Initiative Inc., HiMedia Laboratories Private Limited, Akonni Biosystems Inc.

North America was the largest region in the mycobacterium tuberculosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycobacterium tuberculosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycobacterium tuberculosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imported diagnostic instruments, reagents, and molecular testing equipment have increased overall operational costs in the mycobacterium tuberculosis market, particularly impacting regions dependent on foreign supplies such as Africa, Asia-Pacific, and South America. These tariffs affect segments like PCR instruments, culture media, and antigen kits by raising procurement expenses and delaying supply chains. However, tariffs have encouraged localized manufacturing and investment in domestic diagnostic production, offering long-term cost benefits and improved self-reliance for high-burden countries.

The mycobacterium tuberculosis market research report is one of a series of new reports that provides mycobacterium tuberculosis market statistics, including mycobacterium tuberculosis industry global market size, regional shares, competitors with a mycobacterium tuberculosis market share, detailed mycobacterium tuberculosis market segments, market trends and opportunities, and any further data you may need to thrive in the mycobacterium tuberculosis industry. This mycobacterium tuberculosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mycobacterium tuberculosis is a slow-growing, rod-shaped bacterium that mainly affects the lungs but can also infect other parts of the body. It is the causative agent of tuberculosis (TB), a contagious disease that spreads through airborne droplets released when an infected individual coughs, sneezes, or speaks. The bacterium has a distinctive waxy cell wall composed of mycolic acids, which makes it resistant to drying and contributes to its long-term persistence in the environment.

The main product types related to Mycobacterium tuberculosis include instruments, reagents and consumables, and software solutions. Instruments are medical devices and equipment used for TB diagnosis and research. The disease can be diagnosed through methods such as culture-based techniques, molecular diagnostics, and immunological tests, with routes of administration including oral and injectable. These products and methods are used by end users such as hospitals, diagnostic laboratories, and research institutions.

The mycobacterium tuberculosis market consists of revenues earned by entities by providing services such as tuberculosis strain typing and genotyping services, contract research services, biorepository services, and genomic sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The mycobacterium tuberculosis market also includes sales of diagnostic kits, antibodies, antigens, recombinant proteins, nucleic acid extraction kits, and biosafety equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.